Previous 10 | Next 10 |
IRVINE, Calif. , June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by ...
The World is Not Ending (even in 12 years) and Neither is the Stock Market Chief Strategist Joseph Zidle of Blackstone, I paraphrase: "The trade war will not pull the US or China into recession. A European recession will not bring us down either. The silver lining is that we will see an econ...
New six-month data from a study called CLASP evaluating Edwards Lifesciences' (NYSE: EW ) PASCAL transcatheter valve repair system in patients with clinically significant mitral valve regurgitation (MR) despite optimal medical treatment showed a treatment benefit. The results were prese...
PARIS , May 22, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced strategic clinical and regulatory milestones for its Edwards PASCAL transcatheter va...
IRVINE, Calif. , May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on sch...
Introduction Edwards Lifesciences ( EW ) describes itself this way: ... we continue to lead the field of tissue replacement heart valves and repair products and advanced hemodynamic monitoring, which have helped treat and manage more than 2 million patients worldwide. EW was spun off...
The board of Edwards Lifesciences (NYSE: EW ) has authorized the repurchase of another $1B of its common stock. $1.3B remains under its existing buyback program. More news on: Edwards Lifesciences Corporation, Healthcare stocks news, Read more ...
TORONTO , May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprostheti...
Introduction Those who read my previous articles, including my investment strategy statement , should be familiar with the investment approach that I have been sticking to - buying wonderful businesses at sensible prices. The core here is to evaluate the "wonderfulness," which points to fun...
Introduction Edwards Lifesciences ( EW ) is a leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The company is also an established player hemodynamic monitoring systems in the hospital setting. In the ...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this update in regard to the status of the proposed return of capital announced on June 19, 2024 . The Company has prepared and mailed its ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
2024-07-25 16:00:08 ET Pito Chickering from Deutsche Bank issued a price target of $85.00 for EW on 2024-07-25 13:36:00. The adjusted price target was set to $85.00. At the time of the announcement, EW was trading at $60.58. The overall price target consensus is at $109....